Biohaven Ltd - Understand $bhvn stock

$BHVN Market Cap: $5.084 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$804.3M

TTM

Current Assets

$440.5M

Q3 2024

Current Liabilities

$152.3M

Q3 2024

Current Ratio

289.24%

Q3 2024

Total Assets

$510.5M

Q3 2024

Total Liabilities

$194.5M

Q3 2024

Book Value

$316.0M

Q3 2024

Cash

$84.39M

Q3 2024

P/E

-6.321

Nov 12, 2024 EST

Free Cash Flow

-$389.2M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$0.00	$0.00	$462.5M	$63.63M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change		-100.0%	626.87%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$0.00	$0.00	$462.5M	$63.63M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue			$91.66M	$17.69M
Gross Profit			$370.8M	$45.93M
Gross Profit Margin			80.18%	72.18%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Selling, General & Admin	$62.77M	$130.9M	$708.2M	$460.0M	$134.5M	$34.60M	$18.14M	$5.110M	$2.140M	$470.0K
YoY Change	-52.03%	-81.52%	53.95%	242.16%	288.58%	90.74%	254.99%	138.79%	355.32%
% of Gross Profit			190.98%	1001.61%
Research & Development	$373.3M	$437.1M	$361.3M	$229.0M	$239.7M	$190.0M	$89.44M	$55.53M	$7.560M	$1.010M
YoY Change	-14.6%	20.96%	57.79%	-4.45%	26.18%	112.38%	61.07%	634.52%	648.51%
% of Gross Profit			97.44%	498.58%
Depreciation & Amortization	$6.912M	$1.386M	$24.93M	$9.450M				$10.00K	$0.00	$0.00
YoY Change	398.7%	-94.44%	163.83%
% of Gross Profit			6.72%	20.57%
Operating Expenses	$373.3M	$567.9M	$1.075B	$691.3M	$374.1M	$224.6M	$107.6M	$60.63M	$9.700M	$1.480M
YoY Change	-34.27%	-47.16%	55.48%	84.79%	66.61%	108.73%	77.44%	525.05%	555.41%
Operating Profit	-$436.1M	-$567.9M	-$704.0M	-$645.4M
YoY Change	-23.22%	-19.33%	9.09%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Interest Expense	$0.00	$0.00	-$132.0M	-$109.0M	-$49.24M	-$15.75M	-$18.60M	-$2.960M	$0.00	$0.00
YoY Change		-100.0%	21.14%	121.32%	212.63%	-15.32%	528.38%
% of Operating Profit
Other Income/Expense, Net	$26.50M	-$1.909M	-$7.258M	-$4.020M	-$20.00K	-$150.0K			-$370.0K	-$30.00K
YoY Change	-1488.16%	-73.7%	80.55%	20000.0%	-86.67%				1133.33%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Pretax Income	-$409.6M	-$569.8M	-$843.3M	-$758.4M	-$528.4M	-$240.5M	-$126.2M	-$63.44M	-$10.07M	-$1.510M
YoY Change	-28.13%	-32.43%	11.2%	43.53%	119.74%	90.57%	98.9%	529.99%	566.89%
Income Tax	-$1.383M	$438.0K	$5.073M	$10.23M	$420.0K	$470.0K	$1.010M	$90.00K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$408.2M	-$570.3M	-$846.6M	-$766.8M	-$528.8M	-$240.9M	-$139.2M	-$63.68M	-$10.06M	-$1.460M
YoY Change	-28.43%	-32.64%	10.41%	45.0%	119.5%	73.07%	118.59%	533.0%	589.04%
Net Earnings / Revenue			-183.04%	-1205.09%
Basic Earnings Per Share	-$5.73	-$12.75	-$5.43	-$3.01
Diluted Earnings Per Share	-$5.73	-$12.75	-$13.09	-$13.06	-$10.91	-$6.15	-$5.00	-$2.62	-$0.41	-$0.06

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Short-Term Investments	$381.8M	$465.3M	$364.6M	$355.3M	$316.7M	$264.2M	$131.5M	$23.60M	$1.500M	$1.800M
YoY Change	-17.95%	27.63%	2.62%	12.19%	19.87%	100.91%	457.2%	1473.33%	-16.67%
Cash & Equivalents
Short-Term Investments	$133.4M	$260.5M	$192.6M	$223.2M
Other Short-Term Assets	$46.98M	$75.49M	$122.8M	$88.40M	$8.600M	$8.100M	$5.200M	$500.0K	$400.0K	$0.00
YoY Change	-37.77%	-38.52%	38.9%	927.91%	6.17%	55.77%	940.0%	25.0%
Inventory			$80.61M	$39.60M
Prepaid Expenses
Receivables			$308.3M	$120.1M
Other Receivables			$0.00	$0.00
Total Short-Term Assets	$442.4M	$587.0M	$876.3M	$603.4M	$328.3M	$272.3M	$136.7M	$24.00M	$1.900M	$1.800M
YoY Change	-24.62%	-33.01%	45.22%	83.8%	20.57%	99.2%	469.58%	1163.16%	5.56%
Property, Plant & Equipment	$48.58M	$52.44M	$28.64M	$29.20M	$8.200M	$6.200M	$2.300M	$0.00	$0.00	$0.00
YoY Change	-7.37%	83.08%	-1.91%	256.1%	32.26%	169.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00	$1.200M	$5.300M	$11.40M	$7.800M	$2.800M	$0.00	$0.00
YoY Change			-100.0%	-77.36%	-53.51%	46.15%	178.57%
Other Assets	$2.400M	$2.585M	$115.9M	$14.10M	$2.500M	$0.00	$0.00	$200.0K	$0.00	$0.00
YoY Change	-7.16%	-97.77%	721.82%	464.0%			-100.0%
Total Long-Term Assets	$70.77M	$74.82M	$201.0M	$83.60M	$16.00M	$17.70M	$10.20M	$3.000M	$0.00	$0.00
YoY Change	-5.41%	-62.77%	140.38%	422.5%	-9.6%	73.53%	240.0%
Total Assets	$513.2M	$661.8M	$1.077B	$687.0M	$344.3M	$290.0M	$146.9M	$27.00M	$1.900M	$1.800M
YoY Change
Accounts Payable	$15.58M	$10.70M	$51.68M	$48.50M	$14.10M	$10.80M	$4.700M	$700.0K	$100.0K	$0.00
YoY Change	45.54%	-79.29%	6.56%	243.97%	30.56%	129.79%	571.43%	600.0%
Accrued Expenses	$39.85M	$29.50M	$392.6M	$160.1M	$52.10M	$8.800M	$4.700M	$2.900M	$200.0K	$100.0K
YoY Change	35.06%	-92.48%	145.21%	207.29%	492.05%	87.23%	62.07%	1350.0%	100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$4.200M	$0.00	$0.00
YoY Change							-100.0%
Long-Term Debt Due			$5.410M	$5.600M
YoY Change			-3.39%
Total Short-Term Liabilities	$55.42M	$90.02M	$534.2M	$276.8M	$66.20M	$19.50M	$9.400M	$7.900M	$300.0K	$200.0K
YoY Change	-38.43%	-83.15%	92.99%	318.13%	239.49%	107.45%	18.99%	2533.33%	50.0%
Long-Term Debt	$0.00	$0.00	$1.154B	$715.8M	$247.8M	$117.5M	$0.00	$20.30M	$0.00	$0.00
YoY Change		-100.0%	61.19%	188.86%	110.89%		-100.0%
Other Long-Term Liabilities	$29.81M	$32.99M	$72.19M	$26.60M	$37.80M	$2.000M	$5.500M	$500.0K	$500.0K	$100.0K
YoY Change	-9.63%	-54.3%	171.39%	-29.63%	1790.0%	-63.64%	1000.0%	0.0%	400.0%
Total Long-Term Liabilities	$29.81M	$32.99M	$1.226B	$742.4M	$285.6M	$119.5M	$5.500M	$20.80M	$500.0K	$100.0K
YoY Change	-9.63%	-97.31%	65.14%	159.94%	139.0%	2072.73%	-73.56%	4060.0%	400.0%
Total Liabilities	$85.24M	$123.0M	$1.817B	$1.077B	$351.7M	$139.1M	$14.90M	$28.80M	$700.0K	$200.0K
YoY Change	-30.71%	-93.23%	68.62%	206.31%	152.84%	833.56%	-48.26%	4014.29%	250.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	71.20M shares	44.74M shares	39.38M shares	39.38M shares
Diluted Shares Outstanding	71.20M shares	44.74M shares	39.38M shares	39.38M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $5.0839 Billion

About Biohaven Ltd

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 239 full-time employees. The company went IPO on 2022-09-23. The firm is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.

Industry: Pharmaceutical Preparations Peers: Acrivon Therapeutics, Inc. Anika Therapeutics Inc Arcturus Therapeutics Holdings Inc Stoke Therapeutics Inc Biomea Fusion Inc CONCERT PHARMACEUTICALS, INC. Entrada Therapeutics Inc LEXICON PHARMACEUTICALS, INC. Nurix Therapeutics Inc